Status:
COMPLETED
Exploration of Clonal Hematopoiesis of Indeterminate Potential in Non-ischemic Heart Failure With Reduced Ejection Fraction
Lead Sponsor:
Yonsei University
Conditions:
Heart Failure With Reduced Ejection Fraction
Eligibility:
All Genders
20-80 years
Brief Summary
Clonal hematopoiesis of indeterminate potential (CHIP) refers to a phenomenon in which blood cells with somatic mutation circulate in the peripheral blood due to abnormal proliferation and differentia...
Eligibility Criteria
Inclusion
- As an adult over the age of 19
- A history of left ventricular ejection fraction less than 40% on imaging tests within 3 years (HFrEF diagnosis),
- Have a cardiac MRI taken within 3 months of being diagnosed with HFrEF,
- A person who was diagnosed with non-ischemic heart failure by performing coronary artery imaging (angiography, CT) at the time of diagnosis of HFrEF
Exclusion
- Patients with confirmed ischemic cardiomyopathy (when stenosis of 75% or more of major coronary arteries is confirmed on coronary artery imaging or ischemic cardiomyopathy findings such as transmural late gadolinium enhancement on cardiac MRI)
- History of solid cancer diagnosis and chemotherapy (drugs, radiation)
- History of blood cancer
Key Trial Info
Start Date :
November 23 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 31 2023
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT05981144
Start Date
November 23 2021
End Date
January 31 2023
Last Update
November 13 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Severance hospital
Seoul, South Korea